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Abstract
Double-stranded RNA-activated protein kinase R (PKR) is known to be upregulated by hepatitis C virus (HCV) and
overexpressed in hepatocellular carcinoma (HCC). However, the precise roles of PKR in HCC with HCV infection remain
unclear. Two HCV replicating cell lines (JFH-1 and H77s), generated by transfection of Huh7.5.1 cells, were used for
experiments reported here. PKR expression was modulated with siRNA and a PKR expression plasmid, and cancer-related
genes were assessed by real-time PCR and Western blotting; cell lines were further analyzed using a proliferation assay.
Modulation of genes by PKR was also assessed in 34 human HCC specimens. Parallel changes in c-Fos and c-Jun gene
expression with PKR were observed. Levels of phosphorylated c-Fos and c-Jun were upregulated by an increase of PKR, and
were related to levels of phosphorylated JNK1 and Erk1/2. DNA binding activities of c-Fos and c-Jun also correlated with PKR
expression, and cell proliferation was dependent on PKR-modulated c-Fos and c-Jun expression. Coordinate expression of c-
Jun and PKR was confirmed in human HCC specimens with HCV infection. PKR upregulated c-Fos and c-Jun activities
through activation of Erk1/2 and JNK1, respectively. These modulations resulted in HCC cell proliferation with HCV infection.
These findings suggest that PKR-related proliferation pathways could be an attractive therapeutic target.
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Introduction
Hepatitis C virus (HCV) is a leading cause of chronic liver
disease and is a leading indication for liver transplantation [1].
HCV establishes persistent infection and induces chronic hepatitis,
which leads to liver cirrhosis (LC) and, frequently, to hepatocel-
lular carcinoma (HCC) [2]. However, the precise mechanisms
involved in the induction of heptocarcinogenesis by HCV, and
details of viral effects on tumor progression, remain unclear.
Of the many cellular proteins stimulated by HVC replication,
double-stranded RNA-activated protein kinase R (PKR) appears
to play a key antiviral role [3]. Double stranded-RNA produced by
RNA viral replication is known to be a potent activator of PKR
[4]. Activated PKR, in turn, induces PKR phosphorylation, and
then PKR dimerizes and phosphorylates eukaryotic initiation
factor-2 alpha (eIF2a), which inhibits protein synthesis, including
that of virally-encoded proteins [5]. Moreover, PKR is recognized
as a key arm of the antivirus and antiproliferative effects of
interferon, the most important clinically active agent against HCV
[3]. PKR plays multiple roles in cell growth, differentiation,
apoptosis, and responses to cellular stress occurring during RNA
virus infections [6].
The HCV generates dsRNA during the process of viral
replication, which is thought to activate PKR and then induce
the host antiviral responses [7]. Several reports have indicated that
PKR can directly inhibit HCV replication [7–9]. We previously
reported that PKR was overexpressed and activated in HCC with
HCV infection, as compared with surrounding non-HCC tissues
[10]. Moreover, the level of HCV-RNA was detected and reduced
in HCC compared with surrounding non-HCC tissue, indicating
that the overexpressed PKR in HCC tissues retains its antiviral
function against HCV [10].
PKR was originally thought to function as a tumor suppressor
protein, as it induces the apoptotic response [11,12], and it was
suggested that PKR inhibits cell growth and proliferation [13,14].
However, results of further studies demonstrating functioning
PKR in HCC with HCV infection [10] suggest that it could act as
a tumor stimulator rather than as a suppressor.
The aim of this study was to identify the roles of PKR in HCC
with HCV infection, and to evaluate whether overexpressed PKR
in HCC has beneficial or malignant effects in patients with this
disease.
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Cell Culture and Transfection
The hepatoma cell line Huh 7.5.1 (kindly provided by Dr.
Francis V. Chisari, Department of Immunology and Microbial
Science, The Scripps Research Institute, La Jolla, CA, USA) was
grown and maintained in Dulbecco’s modified Eagle’s medium
(DMEM) (Life Technologies, Carlsbad, CA, USA) supplemented
with 10% fetal bovine serum (FBS) (Life Technologies) and 1%
penicillin. Cells were maintained at 37uC in a humidified
atmosphere of 5% CO2 and 95% air, and the culture medium
was changed three times per week.
HCV-infected HCC cell lines used were JFH1 and H77s. JFH1
cells were generated by transfection of Huh 7.5.1cells with HCV-
RNA synthesized by transcription from pJFH1-full (kindly
provided by Dr. Takaji Wakita, National Institute of Infectious
Diseases, Tokyo, Japan), which encodes the HCV genotype 2a
sequence [15]. For the HCV-RNA transfection, Huh 7.5.1 cells
were resuspended in Opti-MEM I (Life Technologies) containing
10 mg of synthesized HCV-RNA, and were subjected to an electric
pulse (960 mF, 260 V) using the Gene Pulser II apparatus (Bio-
Rad, Richmond, CA, USA). H77s cells were made by transfection
with HCV-RNA transcripted from pH77s-full (kindly provided by
Dr. Stanley M. Lemon, University of North Carolina at Chapel
Hill, Chapel Hill, NC, USA), which encodes the HCV genotype
1a sequence [16,17]; the transfection procedure was the same as
that previously described.
Patients and Liver Specimens
HCC specimens were obtained from patients who underwent
surgery at our institution from 2007 to 2012. Written informed
consent was obtained from all patients. The study protocol
conformed to the ethical guidelines of the Declaration of Helsinki,
and was approved by the Institutional Review Board at Ehime
University Hospital (Approval No. 0710004). This study was
registered by the University Hospital Medical Information
Network (UMIN) Clinical Trials Registry (registration number
000008652). Table 1 lists clinicopathological features of the
34 HCC patients enrolled. Among the 34 specimens, 17 were
from patients with HCV.
Samples of freshly resected liver specimens were incubated with
RNAlater (Life Technologies) overnight at 4uC, and were then
frozen and stored at 280uC until used. Additional samples were
placed on dry ice and frozen immediately, and then stored at
280uC until used for protein extraction.
RNA Interference and PKR Inhibitor Assay
A PKR-specific siRNA (GAG AAU UUC CAG AAG GUG A,
nt. 584–604) was designed using a PKR sequence template
(accession number NM002759), and was then synthesized by
Thermo Fisher Scientific (Waltham, MA, USA) [18]. Control
siRNA was obtained from Cosmo Bio (Tokyo, Japan); c-Fos
siRNA and c-Jun si-RNA were obtained from Thermo Fisher
Scientific. Huh 7.5.1, JFH1 and H77s cell lines at 50% confluence
in 6-well plates were transfected with 50 pM siRNA using
RNAiMax (Life Technologies). For the assay with a PKR
inhibitor, JFH1 or H77s cells were incubated with 300 nM of
PKR inhibitor (Merck, Darmstadt, Deutschland) for 24 h.
PKR Plasmids
Plasmids encoding PKR genes were kindly provided by Dr.
Michael Gale, Jr. (University of Washington, Seattle, WA, USA)
[4]. The plasmid pOS8, which expresses b-galactosidase, was used
as the control plasmid [19]. Each plasmid (1 mg/mL) was
transfected into Huh 7.5.1, JFH1, and H77s at 50% confluence
in 6-well plates using Lipofectamine 2000 (Life Technologies).
RNA Extraction, cDNA Synthesis and Real-time RT-PCR
Total RNA was extracted with TRIzol reagent (Life Technol-
ogies). Reverse transcription was carried out using the RT-PCR kit
(Applied Biosystems, Foster City, CA, USA), and cDNA was
quantified by real-time PCR using LightCycler technology and
SYBR green I dye (Roche Diagnostics, Mannheim, Germany).
Real-time PCR for PKR was performed with 2 ml of purified
cDNA in a reaction SYBR green mixture containing 4 mM
MgCl2, and 5 pM each of forward primer (59-AGCA-
CACTCGCTTCTGAATC-39) and reverse primer (59-
CTGGTCTCAGGATCATAATC-39). PCR consisted of an
initial denaturation step for 10 min at 95uC, then 40 cycles under
the following conditions: 10 sec at 95uC, 10 sec at 58uC, and
15 sec at 72uC. For PCR amplification of GAPDH, c-Fos, c-Jun,
and IL-8, commercial primer sets (Roche Search LC, Heidelberg,
Germany) were used under conditions recommended by the
Table 1. Clinicopathological parameters of patients with hepatocellular carcinoma (HCC) (n=34).
Low PKR (n=17) High PKR (n=17) p-value
Age, years (range) 65 (36–82) 70 (49–79) 0.245
Gender (M/F) 14/3 13/4 1.000
Virus (HBV/HCV/None) 7/7/3 4/10/3 0.510
Child-Pugh (A/B/C) 15/2/0 17/0/0 0.145
Fibrosis (F1/F2/F3/F4) 2/3/3/9 2/3/3/9 1.000
Pathological stage (1/2/3/4) 6/6/3/1 2/9/6/0 0.206
AFP, ng/mL (range) 6.0 (1.6–1525) 25 (0–7720) 0.435
DCP, mAU/mL (range) 65 (13–418820) 212(16–45133) 0.356
PT, % (range) 86.9 (56–181) 85.10 (73–129) 0.790
Tumor size 24 (10–160) 35 (20–75) 0.816
Tumor differentiation (well/moderate/poor) 3/11/3 4/13/0 0.191
Tumor multiplicity (solitary/multiple) 13/4 13/4 1.000
HBV, hepatitis B virus; HCV, hepatitis C virus; AFP, alpha-fetoprotein; DCP, des-carboxyprothrombin; PT, prothrombin time.
doi:10.1371/journal.pone.0067750.t001
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PLOS ONE | www.plosone.org 2 July 2013 | Volume 8 | Issue 7 | e67750Figure 1. Down- and upregulation of PKR gene expression by PKR siRNA or by a PKR-expression plasmid, respectively, in liver
cancer cell lines, Huh 7.5.1, JFH1 and H77s. Cells were transfected with either PKR siRNA or control siRNA, then PKR mRNA was quantified by
real-time RT-PCR; PKR was knocked down (A). Cells were transfected with PKR-expression plasmid (pPKR) or control plasmid (pOS8), then subjected to
real-time RT-PCR; PKR mRNA was upregulated by pPKR (B). Mean 6 SEM of six replicates. **p,0.01. The amount of HCV core protein in JFH1 and
H77s cells were measured by ELISA. HCV core protein was stably expressed in both cell types at least three days after transfection with the HCV-RNA
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described elsewhere [20]. The relative mRNA expression levels of
target host genes were defined by dividing by the amount of
GAPDH mRNA and were then evaluated by statistical analysis.
PCR Array Analysis
For comprehensive analysis of the role of PKR, the RT2
Profiler PCR array system (QIAGEN, Tokyo, Japan) and the
LightCycler system (Roche) were used according to the manufac-
turers’ instructions. Threshold cycle values were analyzed using
web-based PCR array data analysis software found at http://
www.sabiosciences.com/pcr/arrayanalysis.php. Of the kits sup-
plied with the PCR array system, the Cancer PathwayFinder PCR
array was used. Before applying the data, it was determined that
the reverse transcriptase control, cDNA control, and positive PCR
control levels were within the accepted range.
Western Blotting
Proteins were extracted with RIPA buffer comprising 10 mmol/
L Tris, PH 7.4, 150 mmol/L NaCl, 0.5% v/v NP-40 and 1% w/v
sodium dodecyl sulphate (SDS). For Western immunoblotting, 20
mg of protein were applied to lanes of 4–12% Bis-Tris Gels (Life
Technologies), then blotted onto Immobilon-P membranes (Milli-
pore, Bedford, MA, USA) and incubated with the relevant
antibody: anti-beta-actin (Chemicon, Temecula, CA, USA), anti-
PKR (product number: 3210), anti-eIF2a (5324), anti-phospho-
eIF2a (3398), anti-Erk1/2 (4695), anti-phospho-Erk1/2 (4370),
anti-JNK (9252), anti-phospho JNK (4668), anti-c-Jun (9165), anti-
phosphor-c-Jun (3270), anti-c-Fos (2250) (Cell Signaling, Danvers,
MA, USA), anti-phospho PKR (Life Technologies) or anti-
phospho c-Fos (Abcam, Tokyo, Japan) antibody. Appropriate
species-specific conjugated secondary antibody kits were commer-
cially obtained (General Electric, Charles Coffin, NY, USA).
Proteins were detected using the ECL Prime Kit or the ECL Kit
(General Electric). Bands were quantified by normalization to b-
actin using Image J Software (National Institutes of Health
Bethesda, MD, USA).
Cell Proliferation Assay
Cell viability was quantified by a MTS assay (Promega,
Fitchburg, WI, USA). After 24 h of siRNA or plasmid transfection
in 6-well plates, cells were resuspended and then 2610
3 cells were
seeded in 96-well plates. At each time point, cells were treated with
MTS reagent and incubated for 120 min. Absorbance at 450 nm
was recorded. U0126 (Merck), a selective inhibitor of MAP kinase
kinase (MEK), was used to inhibit the c-Fos signaling pathway,
and SP600125 (Merck), a selective inhibitor of JNK, was used to
inhibit the c-Jun signaling pathway.
Enzyme-linked Immunosorbent Assay for IL-8 and HCV
Core Protein
Concentrations of IL-8 were measured in culture supernatant
fluids using an enzyme-linked immunosorbent assay (ELISA) kit
(R&D Systems, Minneapolis, MN, USA). The lower limit of
detection for IL-8 was 31.2 pg/mL. HCV core antigen in cell
lysates was quantified using HCV core antigen ELISA kits (Ortho-
Clinical Diagnostics, Raritan, NJ, USA) following the manufac-
turer’s instructions. The lower limit of detection for HCV was
44.4 fmol/L.
Luciferase Assays
Cells were transfected with a wild type IL-8 promoter
conjugated to firefly luciferase reporter constructs (pIL-8) provided
by Dr. Charalabos Pothoulakis (University of California, Los
Angeles, CA, USA) [21], together with a control reporter plasmid
conjugated with Renilla luciferase reporter constructs, phRL-
TK
Int2 (Promega). Luciferase activities in the samples were
measured 48 h later using the Dual-Luciferase Reporter Assay
System (Promega) and a luminometer (Microtec, Funabashi,
Chiba, Japan). The level of transcription was evaluated as the
ratio of firefly luciferase to Renilla luciferase.
Wound Healing Assay
JFH1 or H77s cells (2610
5/well) were seeded into 6-well plates
and incubated for two days. After confirming that a complete
monolayer had formed, the monolayers were wounded by
scratching lines onto the cultures using a plastic tip. The wells
were then washed once to remove any debris, and observed and
photographed under the microscope. Thereafter, the plates were
incubated at 37uC in 5% CO2 for 48 h, after which the cells were
observed and photographed. The distance that the cells had
migrated was measured on the photomicrographs [22]. The
percent wounded area filled was calculated as follows: {(mean
wounded breadth – mean remaining breadth)/mean wounded
breadth}6100.
c-Fos and c-Jun Transcription Assay
The c-Jun and c-Fos transcription assay was performed using
TransAM
TM (Active Motif, Carlsbad, CA, USA) according to the
manufacturer’s instructions, to detect the DNA binding capacity of
c-Jun or c-Fos containing AP-1 dimers. This assay is equivalent to
the Electrophoresis Mobility Shift Assay (EMSA) used to evaluate
DNA binding capacity [23]. Briefly, JFH1 cells were treated with
PKR siRNA or control siRNA, and after 48 h, 10 mg of nuclear
extract (containing activated transcription factor) was added to
oligonucleotide-coated wells (containing 59-TGAGTCA-39). After
20 min of incubation at room temperature with mild agitation, the
plate was washed, and then incubated with 100 mL/well of diluted
anti-c-Jun or anti-c-Fos antibody for 1 h. The plate was washed
three times and 100 ml HRP-conjugated antibody was added for
1 h. Developing solution was added for 10 min. The reaction was
stopped and absorbance at 450 nm was determined.
Statistical Analysis
All statistical analyses were performed using SPSS 14.0 software
(SPSS, Chicago, IL, USA). Data are expressed as mean 6 SEM.
Statistical differences were determined using the Mann-Whitney U
test. The relationships between c-Fos and c-Jun were expressed as
Pearson product-moment correlation coefficients. P-values , 0.05
were considered to be significant.
(C). The amount of HCV mRNA in JFH1 and H77s cells was measured by real-time RT-PCR. HCV RNA was expressed in both cell types at least three
days after transfection with the HCV-RNA (D). Mean 6 SEM of four replicates. PKR and phosphorylated PKR protein expression evaluated by Western
blotting; results confirmed PKR mRNA data (E).
doi:10.1371/journal.pone.0067750.g001
PKR Increases Proliferation in HCC
PLOS ONE | www.plosone.org 4 July 2013 | Volume 8 | Issue 7 | e67750Figure 2. PKR upregulates c-Fos and c-Jun mRNA and protein in the HCC cell lines with HCV infection, JFH1 and H77s. Cells were
transfected with either control or PKR siRNA, and with either control or PKR-expression plasmid (pPKR). c-Fos mRNA was decreased by PKR
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PKR Knockdown and Upregulation by PKR siRNA and
PKR-encoding Plasmid in HCV-infected HCC Cells
PKR siRNA was designed to knock down PKR gene expression
in liver cancer cell lines [18]. As shown by real-time RT-PCR,
PKR siRNA efficiently knocked down PKR mRNA levels in
Huh7.5.1, JFH1 and H77s cell lines by day 2 after transfection
(Fig. 1A). Use of this method also revealed that the PKR-encoding
plasmid (pPKR) efficiently upregulated PKR mRNA in experi-
mental cell lines by day 2 after transfection (Fig. 1B).
The amount of HCV core protein was measured before (day 0)
and after (days 1–3) transfection with HCV-RNA from pJFH1-full
or pH77s-full. The HCV core protein expressed stably at least
three days after the transfection in both JFH1 and H77s cells
(Fig. 1C). The amount of HCV-RNA was also evaluated by real-
time RT-PCR at the time core protein was measured in JFH1 and
H77s cells (Fig. 1D). The level of HCV-RNA in JFH1 cells on day
3 was decreased, which may reflect the near-confluent cell culture
condition, as reported previously [15]. However, HCV-RNA was
expressed in both cell types at least three days after transfection.
Confirming results reported previously [7], HCV infection
enhanced PKR activation, indicating upregulation of phosphor-
ylated PKR, as shown in Fig. S1. Western blotting demonstrated
the expected corresponding changes in PKR and phosphorylated
PKR protein expression (Fig. 1E). To evaluate the influence of
PKR activation, the expression of phosphorylated eIF2a was also
determined. In the HCV-infected cells (JFH1 and H77s), the
expression of phosphorylated eIF2a was altered by the knockdown
or overexpression of PKR; however, in uninfected Huh 7.5.1 cells,
the expression of phosphorylated eIF2a was not significantly
altered (Fig. 1E). The expression of PKR, phosphorylated PKR,
and phospohorylated eIF2a was quantified by normalizing to
expression of b-actin using Image J Software (Fig. S2).
PKR Upregulates the AP-1 Family Transcription Factors c-
Fos and c-Jun in HCV-infected HCC Cells
Use of the Cancer Pathway Finder PCR array indicated that
several cancer pathways were modulated by up- or downregula-
tion of PKR (Table S1). AP-1 family transcription factors,
including c-Fos and c-Jun, were modulated in JFH1 cells, and
the modulation was more evident in JFH1 than in uninfected
Huh7.5.1 cells. Additionally, the interleukin IL-8 gene, which is a
downstream AP-1 entity, was also altered by the PKR in JFH1
cells. These results indicated that the modulation of c-Fos and c-
Jun by PKR was more evident because the function of PKR was
enhanced by HCV infection. Real-time RT-PCR analysis of JFH1
confirmed modulation of c-Fos and c-Jun genes due to the
expression of PKR with knockdown by PKR siRNA and with
overexpression by PKR plasmid (Fig. 2A–D). Similar trends were
observed in H77s, although some results were not statistically
significant (Fig. 2A–D).
Alteration of the MAPK pathways, including of c-Fos and c-
Jun, by PKR in the HCV-infected HCC cells became the next
focus of investigation. Using Western blot analysis, the effect of
modulation of PKR expression on expression of c-Fos and c-Jun
protein was determined. When expression of PKR was knocked
down by PKR siRNA, c-Fos and c-Jun expression were
downregulated in JFH1 and H77s cells. Moreover, expression of
both phosphorylated c-Fos and phosphorylated c-Jun correlated
with the expression of PKR in JFH1 and H77s cells (Fig. 2E).
Protein levels were quantified by normalizing to b-actin using
Image J Software (Fig. S3).
Mediators upstream of c-Fos and c-Jun in the MAPK signaling
pathway were assessed, and phosphorylated Erk1/2 (upstream of
c-Fos) and phosphorylated JNK1 (upstream of c-Jun) were also
found to positively correlate with expression of PKR (Fig. 2E),
although the total expression levels of Erk1/2 and JNK1 were not
changed. These results indicate that the PKR in HCC with HCV
infection upregulates both the Erk1/2 to c-Fos and JNK1 to c-Jun
signaling pathways. These alterations of MAPK pathways by PKR
were not seen in Huh7.5.1 cells without HCV infection (Fig. 2E).
Additional confirmation that PKR positively regulates c-Fos
and c-Jun signaling pathways was provided by use of the Trans
AM
TM Transcription Factor Assay Kit (Active Motif), which
allows assessment of the DNA-binding capacity of c-Fos and c-Jun
in a manner similar to the electrophoretic mobility shift assay
(EMSA). Downregulation of PKR resulted in decreased DNA-
binding capacity of c-Fos and c-Jun (Fig. 2F). Moreover, after the
treatment by a PKR inhibitor, the expression of phosphorylated
PKR was decreased, as shown by Western blotting analysis (Fig.
S4). In addition, the expression of phosphorylated c-Fos and
phosphorylated c-Jun was obviously decreased (Fig. S4). According
to these results, we suggest that PKR would increase the
phosphorylation of c-Fos and c-Jun, and then activate c-Fos and
c-Jun directly.
PKR Induces Proliferation in HCC Cells with HCV Infection
that Depends on Expression of c-Fos and c-Jun
It is well known that the MAPK pathway is associated with cell
proliferation [24,25]. Therefore, assessments of proliferation were
performed. Monolayer wound healing experiments revealed that
JFH1 and H77s cells recovered more slowly after PKR knockdown
than after transfection with control siRNA (Fig. 3A, B).
Additionally, effects on cell proliferation were evaluated by the
MTS assay. Cell proliferation decreased significantly after PKR
knockdown by PKR siRNA, and increased significantly when
PKR was upregulated by pPKR in the JFH1 and H77s cells
(p,0.01) (Fig. 3C). However these alterations of cell proliferation
were not evident in Huh7.5.1 cells without HCV infection (Fig.
S5).
To determine which signaling pathways are operational in cell
proliferation induced by PKR, inhibition assays, using U0126 to
inhibit the c-Fos pathway and SP600125 to inhibit the c-Jun
pathway, were performed. We confirmed the effects of these
compounds against c-Fos and c-Jun. The expression of phosphor-
ylated c-Fos or phosphorylated c-Jun was evaluated by Western
blotting after 24 h incubation with U0126 or SP600125 in both
JFH1 and H77s cells (Fig. S6). The U0126 decreased phosphor-
ylated c-Fos, but the effect on phosphorylated c-Jun was not
evident in either JFH1 or H77s. SP600125 decreased phosphor-
ylated c-Jun, but the effect on phosphorylated c-Fos was not
evident. JFH1 proliferation was increased after the upregulation of
PKR, and this increase was significantly diminished by either
U0126 or SP600125 (p,0.05) (Fig. 3D). Use of both U0126 and
SP600125 further diminished proliferation (p,0.05) to a level
knockdown (A), and c-Fos was upregulated by PKR overexpression (B). c-Jun mRNA was downregulated by PKR siRNA (C), and upregulated by pPKR
(D). Mean 6 SEM of six replicates. *p,0.05. n.s.: not significant. Protein expression of c-Fos, c-Jun, JNK1, Erk and their phosphorylated forms
determined by Western blotting. Bothc-Fos and c-Jun signaling pathways were activated by PKR (E). DNA binding activities of c-Jun and c-Fos were
downregulated by PKR knockdown (F). Mean 6 SEM of six replicates. *p,0.05.
doi:10.1371/journal.pone.0067750.g002
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(pOS8). These results indicate that both c-Fos and c-Jun signaling
pathways mediate PKR-induced cell proliferation in these HCV-
infected HCC cell lines.
Figure 3. PKR expression was associated with proliferation of JFH1 and H77s cells, which was dependent on both c-Fos and c-Jun
signaling pathways. Wound healing assay: Confluent monolayers of JFH1 or H77s cells transfected with PKR siRNA or control siRNA were wounded
by scratching, and incubated for 48 h (A). Percent wounded area filled in with JFH1 and H77s cells (B). Mean 6 SEM of six replicates. MTS assay:
Proliferation was associated with PKR expression (C). Cells were transfected with pPKR, and then 20 mM c-Jun inhibitor (SP600125) and 10 mM c-Fos
inhibitor (U0126) was added. MTS assay indicated that cell proliferation induced by PKR depended on both c-Jun and c-Fos pathways (D). Mean 6
SEM of 10 replicates. **p,0.01, *p,0.05.
doi:10.1371/journal.pone.0067750.g003
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RT-PCR revealed that IL-8 mRNA was downregulated signif-
icantly by PKR knockdown (p,0.05) (Fig. 4A), as were levels of
secreted IL-8 protein in culture supernatants (Fig. 4B). IL-8
promoter activity also decreased after PKR knockdown (Fig. 4C).
Thus, PKR-modulated c-Jun and c-Fos influenced production of
IL-8, a molecule downstream of c-Jun and c-Fos signaling.
c-Jun and c-Fos were Activated by PKR Expression in
Human HCC Tissue with HCV Infection
The mRNA levels of c-Fos and c-Jun in 34 specimens of human
HCC tissues were determined. The specimens were divided by
median PKR mRNA level into two groups of higher (High PKR)
and lower (Low PKR) levels. Median values for PKR mRNA in all
HCC specimens, in HCC specimens with HCV infection, and in
HCV-unrelated HCC specimens were 1.00610
23, 1.20610
23,
and 8.00610
24 copy ratio (PKR mRNA/GAPDH mRNA),
respectively.
When considering all 34 HCC specimens together, the High
PKR Group had significantly higher levels of c-Jun mRNA than
did the Low PKR group (p=0.024). For HCC specimens with
HCV infection, the c-Jun mRNA level of the High PKR group
was significantly higher than that of the Low group (p=0.021), but
this difference was not evident in the HCC specimens without
HCV infection (Fig. 5A). The levels of c-Fos mRNA did not differ
significantly among these groups (Fig. 5B). However, a positive
Figure 4. The PKR upregulates IL-8 expression and secretion. IL8 mRNA levels were downregulated by PKR knockdown (A). Supernatants of
cultured cells were collected, and IL-8 levels were determined by ELISA. Secreted IL-8 was downregulated by PKR knock-down (B). Assays using the IL-
8 promoter-luciferase reporter plasmid: IL-8 promoter activities were downregulated by PKR knockdown (C). Mean 6 SEM of six replicates. *p,0.05.
doi:10.1371/journal.pone.0067750.g004
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(r=0.816, P,0.001) (Fig. 5C).
Additional Western blotting was performed to evaluate phos-
phorylated c-Jun and c-Fos levels in the human HCC specimens.
The four specimens having the highest and the four having the
lowest expression of PKR proteins were assayed. The specimens
from the High PKR group had greater expression of phosphor-
ylated c-Jun and phosphorylated c-Fos (Fig. 5D). These results
indicate that PKR expression is related to activation of c-Jun and
c-Fos in the human HCC specimens used in this study.
Discussion
Protein kinase R (PKR) is well known as a key molecule in
elimination of HCV, especially during interferon use [18]. A
previously reported study demonstrated that PKR is overexpressed
in HCC tissues; however, its precise role in HCC-related
phenomena remains controversial. It was reported that PKR
plays a tumor suppressor function through the p53 signaling
Figure 5. c-Jun and c-Fos were activated by the expression of PKR in human HCC tissues with HCV infection. RNA from HCC specimens
of 34 patients, 17 HCC specimens with HCV infection (HCC positive HCC), and 17 HCC without HCV infection (HCC negative HCC). Each group was
divided into two subsections by the median PKR mRNA values: Low PKR and High PKR. c-Jun mRNA (A) and c-Fos mRNA (B) were measured. c-Fos
mRNA significantly correlated with c-Jun mRNA (r=0.816, P,0.001) (C). The four human HCC specimens having the highest (High PKR) and the four
having the lowest (Low PKR) PKR protein expression were analyzed by Western blotting. c-Jun and c-Fos in the High PKR group were activated more
than in the Low PKR group (D).
doi:10.1371/journal.pone.0067750.g005
Figure 6. Model of the role of PKR in cell proliferation and
relationships between PKR and other molecules associated
with the c-Jun and c-Fos pathways. SP600125: inhibitor of c-Jun
pathway. U0126: inhibitor of c-Fos pathway.
doi:10.1371/journal.pone.0067750.g006
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recent reports indicate that PKR can directly stimulate cell growth
through the p38 MAPK and NF-kB pathways [27,28]. The
p38MAPK pathway is known to play a critical role in the
pathogenesis of various malignancies [29,30], and NF-kB is known
to regulate inflammatory cytokines, growth factors, angiogenic
factors and anti-apoptotic effects, each of which can contribute to
the process of carcinogenesis [31]. Initially, the focus of the current
study was on those molecules; however, the p53, p38MAPK and
NF-kB pathways were not altered by PKR expression in the HCC
cell lines with HCV infection that were used (Table S1). Moreover,
results from examination of the cell cycle by FACS analysis and
staining with propidium iodide revealed that the proportion of the
sub-G1 population was not altered by the downregulation or
upregulation of PKR (data not shown). It is possible that the role of
PKR in HCC with HCV infection has a specialized function
because PKR is directly induced and activated by HCV;
otherwise, levels of activated PKR would be higher in this setting
than in other cancers.
This study demonstrated that PKR is more highly activated in
HCC cells with HCV infection, and that under those conditions,
the over-activated PKR upregulates c-Jun and c-Fos through
activation of JNK1 and p44/42 MAPK (Erk1/2), respectively
(Fig. 6). Upregulation of c-Jun and c-Fos was dependent on tumor
cell proliferation, and in turn induced IL-8. Activation of c-Jun
and c-Fos was also observed in the human HCC specimens, in
which PKR was overexpressed. The functions of over-activated
PKR would be expected to have negative effects on prognosis for
HCC patients with HCV infection, and could be related to the
worse outcomes observed in this setting.
c-Jun and c-Fos are members of the activating protein 1 (AP-1)
family. These proteins are diametric transcription factors [32] that
bind to DNA [33]. The AP-1 family is implicated in carcinogen-
esis, and it regulates genes that include important regulators of
invasion and metastasis, proliferation, differentiation, and survival
[34]. Among the AP-1 proteins, c-Jun is able to both homo- and
heterodimerize, whereas c-Fos is unable to homodimerize. In vitro
studies have shown that Jun-Fos heterodimers are more stable and
have stronger DNA-binding activity than Jun-Jun homodimers
[35]. The current results in human HCC tissues indicated a
positive correlation between levels of c-Fos and c-Jun (Figure 6C),
suggesting that c-Jun and c-Fos hetero-dimers could be the main
moieties binding to DNA in HCC.
Previous reports indicated that c-Jun is important for hepato-
genesis [36,37]. In mice with inactivated c-Jun, the number and
size of hepatic tumors caused by diethylnitrosamine (DEN)
treatment were reduced [38], suggesting that c-Jun may have an
important role in tumor progression. On the other hand, persistent
expression of c-Fos would also play an important role in tumor
progression. c-Fos is known to induce depolarization and
acquisition of an invasive phenotype, a process generally referred
to as ‘‘epithelial to mesenchymal transition’’ (EMT) [39], resulting
in tumor growth and metastasis. In a previous study of 150 human
HCC samples, c-Fos expression was significantly higher in tumors
than in non-tumor tissue (p,0.0001) [40], and elevated JNK1 (the
c-Jun upstream activator) activity was identified in more than 50%
of HCC samples relative to non-cancerous liver tissue [41]. In the
current study, upregulation of c-Jun was identified in HCC tissues
with higher expression of PKR. These findings suggest that
alterations of c-Jun and c-Fos pathways in HCC with HCV
infection may have important roles in tumor progression.
The direct effects of HCV on the c-Jun and c-Fos pathways
must be considered. A previous report suggests that HCV proteins
can modulate MAPK (Erk) signaling by targeting multiple steps
along the signaling pathways [42]. Another report indicated that
HCV E2 protein activates the MAPK (Erk) pathway and promotes
cell proliferation in human hepatoma Huh-7 cells [42]. The
current results suggest that PKR may activate Erk1/2 directly
through phosphorylation. The previous reports did not describe
PKR expression, and it is possible HCV proteins modulate the
MAPK (Erk) pathway through the activation of PKR. On the
other hand, one previous report described negative regulation of
Erk by PKR, but positive regulation of JNK by PKR in mouse
embryonic stem cells [43]. HCV infection may alter the role of
PKR with respect to the c-Jun and c-Fos pathways: differences in
this role in HCC as compared to other cancer types need to be
determined in future studies. Recently, the multikinase inhibitor,
sorafenib, was reported to be effective for treatment of HCC [44].
Sorafenib was shown to inhibit c-Raf, Erk and MAPK/Erk kinase
(MEK) [44], and therefore would have a greater effect in HCC
patients with HCV. The role of PKR in treatment with sorafenib
should be addressed in future analyses.
Over-activated PKR in HCC with HCV infection upregulated
production of IL-8 in this study. IL-8 occurs downstream to AP-1
[45], and is known to contribute to angiogenesis and proliferation
[46] in various cancers. It is known that HCV NS5A can induce
IL-8 mRNA and protein [47], and in a previous report, serum
levels of IL-8 were increased significantly in patients with chronic
hepatitis C compared with normal controls [48]. Activated PKR
could contribute to the upregulation of IL-8 in patients with HCV,
which could in turn contribute to tumor progression. The precise
role of upregulated IL-8 in HCC with HCV infection also needs to
be ascertained in detail in future studies.
In conclusion, the current results demonstrate that over-
activated PKR in HCC with HCV infection contributes to
proliferation due to the upregulation of c-Jun and c-Fos by
activation of JNK and Erk1/2. Such effects of over-activated PKR
would be expected to have negative effects on treatment of HCC
patients with HCV infection. The role of PKR and its importance
for elimination of HCV in patients with HCC needs to be
reconsidered. Over-activated PKR potentially could serve as a
therapeutic target in HCC patients with HCV infection; further
studies are warranted to investigate this possibility.
Supporting Information
Figure S1 HCV infection upregulates the expression of
phosphorylated PKR protein. 24 h after transfection of Huh
7.5.1cells with pJFH1-full or pH77s-full, protein expression of
PKR and phosphorylated PKR were determined by Western
blotting. In the HCV-infected HCC cells (JFH1 and H77s),
expression of phosphorylated PKR was increased significantly
compared with that in Huh7.5.1 cells (HCV-uninfected HCC
cells).
(TIF)
Figure S2 Quantification of Figure 1E Western blot
bands. Bands in Figure 1E indicating PKR, phosphorylated PKR
and phosphorylated eIF2a were quantified and normalized using
the quantified corresponding beta-actin band.
(TIF)
Figure S3 Quantification of Figure 2E Western blot
bands. Bands in Figure 2E indicating c-Fos, c-Jun, phosphory-
lated c-Fos and phosphorylated c-Jun were quantified and
normalized using the quantified corresponding beta-actin band.
(TIF)
Figure S4 PKR inhibitor decreased phosphorylation of
c-Fos and c-Jun. PKR inhibitor (300 nM) was added to JFH1
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PLOS ONE | www.plosone.org 10 July 2013 | Volume 8 | Issue 7 | e67750and H77s. After a 24 h treatment, the expression of PKR, c-Fos, c-
Jun, phosphorylated PKR, phosphorylated c-Fos, and phosphor-
ylated c-Jun were evaluated by Western blotting. PKR inhibitor
decreased phosphorylated PKR, and phosphorylated c-Jun and
phosphorylated c-Fos proteins.
(TIF)
Figure S5 Enhancement of cell proliferation was not
evident in Huh7.5.1 cells without HCV infection. Wound
healing assay: Confluent monolayers of Huh7.5.1 cells transfected
with PKR siRNA or control siRNA were wounded by scratching
and then incubated for 48 h (A). Percent wounded area filled in
with Huh7.5.1 cells. Mean 6 SEM of six replicates (B). MTS
assay: Proliferation was not associated with PKR expression in
Huh7.5.1 (C). Mean 6 SEM of 10 replicates.
(TIF)
Figure S6 U0126 inhibits c-Fos signaling pathway, and
SP600125 inhibits c-Jun signaling pathway, in JFH1 and
in H77s cells. 10 mM c-Fos inhibitor (U0126) or 20 mM c-Jun
inhibitor (SP600125) was added to JFH1 and H77s cell cultures.
After a 24 h treatment, levels of phosphorylated c-Fos and
phosphorylated c-Jun were evaluated by Western blotting.
U0126 decreased phosphorylated c-Fos, and SP600125 decreased
phosphorylated c-Jun.
(TIF)
Table S1 PCR array analysis of the effect of PKR up- and
down-regulation on cancer-related genes.
(DOC)
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